Thus, collectively there is now substantial evidence that delivery of VEGF-C(C156S) by a variety of routes in experimental animal models can significantly improve the outcome post-MI; through targeting increased lymphangiogenesis to reduce oedema and enhance the clearance of immune cells. Here, VEGFC is linked to myocardial infarction.